Covid-19 Research

Research Article

Formulation Development, Analytical Validation and In vitro Assessment of a Generic Lymecycline 408 mg Hard Capsule

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Research Article
Subject Medicine Group
OCLC JBRES Record
Ali Raza, Noor Zulfi qar*, Yameen HM, Fatima A, Rizwan M, Mahmood I, Ain QU and Imran M
Issue: Volume7-Issue3
Pages: 1-20
Received: 2026-02-17
Accepted: 2026-03-06
Published: 2026-03-09

Abstract

This study documents the stepwise development and evaluation of a generic Lymecycline 408 mg hard gelatin capsule manufactured locally in Pakistan. The formulation process began with the selection of suitable pharmacopeial excipients after conducting accelerated compatibility testing to ensure that no undesirable physical or chemical interactions occurred with the active ingredient. Based on these preliminary investigations, a stable capsule composition was finalized. The finished capsules were evaluated according to British Pharmacopoeia requirements. All tested quality attributes, including assay, dissolution behavior, content uniformity, and moisture content, were found to comply with the specified limits. These results confirmed the consistency and integrity of the developed dosage form. Quantitative analysis of Lymecycline was carried out using a high-performance liquid chromatography method that was validated prior to routine application. During validation, parameters such as specificity, precision under repeat and intermediate conditions, accuracy through recovery assessment, robustness against minor variations, and system suitability were carefully examined. The method demonstrated reliable and reproducible performance in line with internationally accepted regulatory standards. To assess comparative in-vitro performance, dissolution testing was performed using the USP paddle method in media representing gastric and intestinal pH conditions (pH 1.2, 4.5, and 6.8). In all cases, more than 85% of the drug was released within one hour. Statistical comparison with the reference product, Tetralysal® 300 mg, showed acceptable similarity and difference factor values, indicating comparable release profiles. Overall, the data support that the developed formulation performs equivalently to the reference product and may be considered suitable for local production and further regulatory processing.

FullText HTML FullText PDF DOI: 10.37871/jbres2278 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2026 Raza A, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Raza A, Zulfi qar N, Yameen HM, Fatima A, Rizwan M, Mahmood I, Ain QU, Imran M. Formulation Development, Analytical Validation and In vitro Assessment of a Generic Lymecycline 408 mg Hard Capsule. J Biomed Res Environ Sci. 2026 Mar 09; 7(3): 20. Doi: 10.37872/jbres2278

Subject area(s)

Pharmaceutica Analytica ActaTherapeuticsPharmacology

References

  1. Shanmuganathan D. Teratogenicity of tetracyclines. World J Pharm Res. 2025.
  2. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001 Jun;65(2):232-60 ; second page, table of contents. doi: 10.1128/MMBR.65.2.232-260.2001. PMID: 11381101; PMCID: PMC99026.
  3. Demain AL. Antibiotics: natural products essential to human health. Med Res Rev. 2009 Nov;29(6):821-42. doi: 10.1002/med.20154. PMID: 19291695.
  4. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1995 Jul;50(1):73-101. doi: 10.2165/00003495-199550010-00007. PMID: 7588092.
  5. Leyden JJ. Therapy for acne vulgaris. N Engl J Med. 1997 Apr 17;336(16):1156-62. doi: 10.1056/NEJM199704173361607. PMID: 9099661.
  6. Stachelek M. Overcoming bacterial resistance to antibiotics: The urgent need a review. Annals of Animal Science. 2021.
  7. Fukuda Y. New approaches to overcoming bacterial resistance. Drugs Future. 2009;34(2):127-136. doi: 10.1358/dof.2009.034.02.1313642.
  8. Galluccio G. Advances in the pathogenesis and treatment of rosacea: A phenotype based therapeutic approach. Cosmetics. 2024.
  9. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, Shalita AR, Lozada VT, Berson D, Finlay A, Goh CL, Herane MI, Kaminsky A, Kubba R, Layton A, Miyachi Y, Perez M, Martin JP, Ramos-E-Silva M, See JA, Shear N, Wolf J Jr; Global Alliance to Improve Outcomes in Acne. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009 May;60(5 Suppl):S1-50. doi: 10.1016/j.jaad.2009.01.019. PMID: 19376456.
  10. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006 Aug;58(2):256-65. doi: 10.1093/jac/dkl224. Epub 2006 Jul 1. PMID: 16816396.
  11. Chukwudi CU. rRNA Binding Sites and the Molecular Mechanism of Action of the Tetracyclines. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4433-41. doi: 10.1128/AAC.00594-16. PMID: 27246781; PMCID: PMC4958212.
  12. Schreiner A, Digranes A. Pharmacokinetics of lymecycline and doxycycline in serum and suction blister fluid. Chemotherapy. 1985;31(4):261-5. doi: 10.1159/000238345. PMID: 4028871.
  13. Abuelella KE . Polymer-Based Biomaterials for Wound Healing: Advances in Natural, Synthetic and Hybrid Biodegradable Polymers for Scar Reduction and Skin Regeneration. Bulletin of Pharmaceutical Sciences Assiut University.2025;48(1):135-174.
  14. Christiansen CS, Høye S, Lindbaek M, Halvorsen JA, Emilsson L. Acne management in Norway: GP and dermatologist prescriptions (2012-2019): a nationwide overview. BJGP Open. 2025 Oct 27;9(3):BJGPO.2024.0211. doi: 10.3399/BJGPO.2024.0211. PMID: 40393778; PMCID: PMC12728883.
  15. Imran M. In-vitro evaluations of lincomycin hydrochloride capsules: Development, validation, and compatibility. Multidisciplinary Surgical Research Annals. 2025;3(4):1-15. doi: 10.5281/zenodo.17538823.
  16. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003 Sep;49(3 Suppl):S200-10. doi: 10.1067/s0190-9622(03)01154-x. PMID: 12963896.
  17. Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, Lapins J, Matusiak L, Prens EP, Revuz J, Schneider-Burrus S, Szepietowski JC, van der Zee HH, Jemec GB. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44. doi: 10.1111/jdv.12966. Epub 2015 Jan 30. PMID: 25640693.
  18. Marasca C, Tranchini P, Marino V, Annunziata MC, Napolitano M, Fattore D, Fabbrocini G. The pharmacology of antibiotic therapy in hidradenitis suppurativa. Expert Rev Clin Pharmacol. 2020 May;13(5):521-530. doi: 10.1080/17512433.2020.1762571. Epub 2020 Jul 7. PMID: 32364806.
  19. Drucker AM, Hollestein L, Na Y, Weinstock MA, Li WQ, Abdel-Qadir H, Chan AW. Association between antihypertensive medications and risk of skin cancer in people older than 65 years: a population-based study. CMAJ. 2021 Apr 12;193(15):E508-E516. doi: 10.1503/cmaj.201971. PMID: 33846199; PMCID: PMC8087333.
  20. Ak M. A comprehensive review of acne vulgaris. J Clin Pharm. 2019.
  21. Diaz DA, Colgan ST, Langer CS, Bandi NT, Likar MD, Van Alstine L. Dissolution Similarity Requirements: How Similar or Dissimilar Are the Global Regulatory Expectations? AAPS J. 2016 Jan;18(1):15-22. doi: 10.1208/s12248-015-9830-9. Epub 2015 Oct 1. Erratum in: AAPS J. 2016 May;18(3):792. doi: 10.1208/s12248-015-9835-4. PMID: 26428517; PMCID: PMC4706290.
  22. Bhujbal S, Rupenthal ID, Agarwal P. Development and validation of a stability-indicating HPLC method for assay of tonabersat in pharmaceutical formulations. Methods. 2024 Nov;231:178-185. doi: 10.1016/j.ymeth.2024.10.001. Epub 2024 Oct 3. PMID: 39368764.
  23. Kumar SL. Quality-by-design driven analytical method (AQbD) development and validation of HPLC–UV technique to quantify rivastigmine hydrogen tartrate in lipidic nanocarriers: Forced degradation, and assessment of drug content and in vitro release studies. Microchemical Journal. 2023.
  24. Zulfiqar N. Nanotechnology inspired approaches for improving the stability of cephradine dry suspension: The role of pharmaceutical excipients. Mathews Journal of Pharmaceutical Science. 2025.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership